RPG Life Sciences Ltd

₹ 2,955 -3.13%

28 Sep - close price

rpglifesciences.com BSE: 532983 NSE: RPGLIFE

About

Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients^[1]

Key Points

Business Overview:^[1]
RPGLS is a part of the RPG Group. It started as a joint venture with G.D Searle and was renamed when G.D Searle withdrew its India operations. Currently, the group has major listed companies like KEC International, CEAT, Zensar Tech, etc.
RPGLS is an integrated research based pharmaceutical company operating in domestic and international markets in branded formulations, global generics and APIs

Website BSE NSE

Market Cap ₹ 4,887 Cr.
Current Price ₹ 2,955
High / Low ₹ 3,130 / 1,731
Stock P/E 41.8
Book Value ₹ 366
Dividend Yield 0.81 %
ROCE 25.7 %
ROE 19.3 %
Face Value ₹ 8.00

Add ratio to table

Edit ratios

Pros

Company is almost debt free.

Cons

Stock is trading at 8.07 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	173	143	169	182	180	177	196
	124	118	133	143	140	144	152
Operating Profit	49	25	35	39	40	33	43
OPM %	28%	18%	21%	21%	22%	19%	22%
	3	115	5	16	-5	14	5
Interest	0	0	0	0	0	0	1
Depreciation	5	5	5	5	5	6	6
Profit before tax	47	135	35	49	29	40	41
Tax %	26%	13%	26%	25%	24%	26%	26%
	35	117	26	37	22	30	31
EPS in Rs	21.12	70.95	15.90	22.28	13.38	18.08	18.60
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2025	Mar 2026	TTM
	653	708	734
	493	560	579
Operating Profit	161	148	155
OPM %	25%	21%	21%
	95	29	29
Interest	2	2	1
Depreciation	21	21	22
Profit before tax	233	154	160
Tax %	21%	25%
	183	115	120
EPS in Rs	110.79	69.64	72.34
Dividend Payout %	22%	34%

Compounded Sales Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	8%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	-5%

Stock Price CAGR
10 Years:	20%
5 Years:	34%
3 Years:	32%
1 Year:	32%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	%
Last Year:	19%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2025	Mar 2026
Equity Capital	13	13
Reserves	517	592
	0	20
	127	168
Total Liabilities	658	793
	172	197
CWIP	16	23
Investments	127	85
	343	488
Total Assets	658	793

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2025	Mar 2026
	78	56
	-42	86
	-27	-21
Net Cash Flow	9	122
Free Cash Flow	151	-9
CFO/OP	81%	63%

Ratios

Consolidated / View Standalone

	Mar 2025	Mar 2026
Debtor Days	48	60
Inventory Days	159	179
Days Payable	135	141
Cash Conversion Cycle	72	99
Working Capital Days	45	64
ROCE %		26%

Insights

In beta

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

API Revenue Share
% of total revenue

xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
			x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx
			x				xx	xx	xx	xx
							xx.xx	xx.xx	xx.xx	xx.xx
							xx,xxx	xx,xxx	xxx,xxx	xxx,xxx
									xx.xx
		x.xx	x.xx					x.xx		x.xx

Please log in to see hidden values.

Domestic Formulations Revenue Share
% of total revenue

International Formulations Revenue Share
% of total revenue

Sales Force Productivity (PCPM - Overall)
INR Lakhs per rep per month

New Product Contribution (DF sales from launches since FY19)
% of DF sales

DF Growth vs IPM Market Growth
% YoY growth

Doctors Enrolled on RPG Serv Platform
Number of doctors

Specialty Sales Force Productivity (PCPM)
INR Lakhs per rep per month

R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	72.82%	72.82%	72.82%	72.82%	72.82%	72.95%	72.95%	72.95%	72.95%	72.95%	72.95%	72.95%
	0.46%	0.56%	0.90%	1.15%	1.35%	1.30%	1.46%	1.35%	1.11%	1.00%	0.87%	0.95%
	1.57%	1.77%	2.16%	2.61%	5.45%	6.06%	6.14%	6.49%	6.70%	7.04%	7.45%	8.68%
	25.15%	24.85%	24.12%	23.44%	20.40%	19.70%	19.46%	19.22%	19.23%	19.01%	18.72%	17.42%
No. of Shareholders	21,088	21,866	22,137	22,232	23,481	24,891	24,867	25,832	26,657	25,905	25,282	23,886

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Jun 2026
	67.48%	69.22%	70.99%	72.07%	72.07%	72.07%	72.82%	72.82%	72.95%	72.95%	72.95%
	0.08%	0.02%	0.00%	0.01%	0.01%	0.12%	0.38%	0.90%	1.46%	0.87%	0.95%
	0.25%	0.52%	0.27%	0.37%	0.03%	0.01%	0.11%	2.16%	6.14%	7.45%	8.68%
	32.18%	30.24%	28.74%	27.55%	27.89%	27.80%	26.70%	24.12%	19.46%	18.72%	17.42%
No. of Shareholders	16,794	15,207	15,649	15,942	18,701	22,821	20,837	22,137	24,867	25,282	23,886

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Sep 2026

Transcript

AI Summary
PPT
Jul 2026

Transcript

AI Summary
PPT
May 2026
Transcript PPT REC
Apr 2026

Transcript

AI Summary
PPT
Jan 2026

Transcript

AI Summary
PPT
Oct 2025
Transcript PPT REC
Jul 2025

Transcript

AI Summary
PPT
Jun 2025

Transcript

AI Summary
PPT
Apr 2025
Transcript PPT REC
Nov 2024

Transcript

AI Summary
PPT
Sep 2024
Transcript
PPT
REC
Jul 2024

Transcript

AI Summary
PPT
Jun 2024

Transcript

AI Summary
PPT
May 2024
Transcript PPT
Feb 2024

Transcript

AI Summary
PPT
Oct 2023
Transcript PPT
Jul 2023

Transcript

AI Summary
PPT
Jun 2023

Transcript

AI Summary
PPT
May 2023
Transcript PPT
Feb 2023

Transcript

AI Summary
PPT
Feb 2023

Transcript

AI Summary
PPT
Oct 2022
Transcript PPT
Sep 2022

Transcript

AI Summary
PPT
Aug 2022

Transcript

AI Summary
PPT
May 2022
Transcript PPT
Feb 2022

Transcript

AI Summary
PPT
Jan 2022

Transcript

AI Summary
PPT
Nov 2021
Transcript PPT
Aug 2021

Transcript

AI Summary
PPT
Jun 2021

Transcript

AI Summary
PPT
Jun 2019

Transcript

AI Summary
PPT
Jun 2018

Transcript

AI Summary
PPT
Nov 2017

Transcript

AI Summary
PPT
Jun 2017

Transcript

AI Summary
PPT
Nov 2016

Transcript

AI Summary
PPT
Jun 2016

Transcript

AI Summary
PPT